Brain Amine Concentrations after Monoamine Oxidase Inhibitor Administration

Jones, Adele; Pare, C. M. B.; Nicholson, W. J.; Price, Kathleen; Stacey, R. S.

doi:10.1136/bmj.1.5791.17

Cited by 51 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2, the effects of RS-2232 on monoamine content disappeared a few hours after administration of the compound in contrast to irreversible MAO inhibitors , their effects lasting for several days (28,29). Therefore, it is suggested that RS-2232 acts as a reversible MAO inhibitor in vivo in mouse brain (see the following paper).…”

Section: Discussionmentioning

confidence: 97%

Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.

et al. 1987

View full text Add to dashboard Cite

Abstract-The effects of RS-2232, a new antidepressant, on the levels of mono amines, precursor amino acids and their related metabolites in mouse brain were investigated and compared with some clinically effective antidepressants. RS 2232 (3, 10 and 30 mg/kg, p.o.) increased the levels of norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) dose-dependently, 60 min after administration. Tyrosine (TYR) levels were not changed, but tryptophan (TRP) was significantly increased by 20% at 30 mg/kg of the compound. On the other hand, DA metabolites such as 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were significantly reduced at all doses. 5-Hydroxy indoleacetic acid (5-HIAA), a 5-HT metabolite, was decreased by 32% at 10 mg/kg. These changes caused by RS-2232 administration were similar to those of the classical inhibitor of monoamine oxidase (MAO), isocarboxazid (ISO), but rather different from those of imipramine (IMP) and mianserin (MIA). RS-2232 and

show abstract

Section: Discussionmentioning

confidence: 97%

Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.

et al. 1987

View full text Add to dashboard Cite

show abstract

“…2). However, brains obtained at autopsy from depressive geriatric subjects with terminal diseases, treated with the irreversible MAO-A inhibitor antidepressant, clorgyline (Johnston, 1968) (Riederer and Youdim, 1986) sistent, highly significant increases of noradrenaline and serotonin, with a much smaller effect on brain dopamine (Youdim etal., 1971;Bevan Jones, 1972) (Fig. 3).…”

Section: Mao-a Inhibitionmentioning

confidence: 98%

Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition

Youdim

Riederer

1993

J. Neural Transmission

View full text Add to dashboard Cite

The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors. These selective inhibitors are demonstrating unique pharmacology and initial controlled clinical studies are providing evidence to support their action as anti-depressants and anti-Parkinson's disease drugs and possibly as neuroprotectors. Thirty years of experience with non-selective MAO inhibitors has resulted in a better understanding and management of the new generation of MAO inhibitors. Because of their selective action on the specific forms of MAO, which results in selective elevation of brain noradrenaline and serotonin on the one hand and dopamine and phenylethylamine on the other, it is hoped that these drugs will be able to elucidate the functional roles of MAO-A and B subtypes with regards to dopamine metabolism in the human brain.

show abstract

Introduction to Clinical Aspects of Monoamine Oxidase Inhibitors in the Treatment of Depression

Pare

1976

Ciba Foundation Symposium 39 ‐ Monoamine Oxidase and Its Inhibition

View full text Add to dashboard Cite

Brain Amine Concentrations after Monoamine Oxidase Inhibitor Administration

Cited by 51 publications

References 15 publications

Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.

Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.

Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition

Introduction to Clinical Aspects of Monoamine Oxidase Inhibitors in the Treatment of Depression

Contact Info

Product

Resources

About